Malvern’s Recro Pharma Prepping To Inject Second Pain Product Into Market

By

photo credit: cafemama via photopin cc

The promise of bringing pain relief to patients right out of surgery without using narcotics is another step closer to reality for a Malvern specialty pharmaceutical company.

With its first product, Dex-IN, approaching Phase III status, Recro Pharma recently bought up its second Phase III-ready treatment, IV/IM meloxicam, and the manufacturing capacity to propel the business into the future.

Recro Pharma completed the acquisition of assets from Alkermes for $50 million up-front and up to $120 million more in potential milestone payments.

Recro CEO Gerri Henwood (Courtesy of www.bizjournals.com)
Recro CEO Gerri Henwood (Courtesy of www.bizjournals.com)

“Completion of this transaction is a significant corporate milestone for Recro Pharma, as it provides a second, complementary, Phase III-ready acute pain product to our portfolio and adds infrastructure and cash flow which may help fund the development of our pipeline in the future,” President and CEO Gerri Henwood said in a press release.

IV/IM meloxicam is a proprietary “long-acting COX-2 nonsteroidal anti-inflammatory drug for moderate to severe acute pain;” Dex-IN is a “proprietary intranasal formulation of dexmedetomidine,” a sedative, that recently cleared an interim analysis and trial adjustment.

“The completion of the interim analysis is an important milestone for Recro Pharma, and we are encouraged by this outcome,” Henwood said in a second press announcement. “We eagerly anticipate the completion of this trial and remain on track to report top-line results by mid-year 2015. There remains a significant unmet need for non-opioid analgesics for acute post-operative pain, a need we continue to believe may be addressed by Dex-IN.”

_______

Top photo credit: cafemama via photopin cc

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Advertisement
Creative Capital logo